캐나다 - 영어 - Health Canada

teva canada limited - ranibizumab - solution - 10mg - ranibizumab 10mg

캐나다 - 영어 - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

캐나다 - 영어 - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

samsung bioepis nz limited - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose dihydrate water for injection - byooviz is indicated for: - the treatment of neovascular (wet) age-related macular degeneration (amd), - the treatment of visual impairment due to diabetic macular oedema (dme), - treatment of proliferative diabetic retinopathy (pdr), - the treatment of visual impairment due to choroidal neovascularisation (cnv), - the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), - the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo).

캐나다 - 영어 - Health Canada

hoffmann-la roche limited - ranibizumab - solution - 100mg - ranibizumab 100mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: water for injections; polysorbate 20; trehalose dihydrate; histidine hydrochloride monohydrate; histidine - byooviz (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),,- the treatment of visual impairment due to diabetic macular oedema (dme),,- treatment of proliferative diabetic retinopathy (pdr),,- the treatment of visual impairment due to choroidal neovascularisation (cnv),,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - ranibizumab, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; histidine - raniviz (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd),,? the treatment of visual impairment due to diabetic macular oedema (dme),,? treatment of proliferative diabetic retinopathy (pdr),,? the treatment of visual impairment due to choroidal neovascularisation,,? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,not recommended for use in preterm infants.

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ranibizumab -

싱가포르 - 영어 - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - ranibizumab - injection, solution - ranibizumab 1.65mg/0.165ml

요르단 - 영어 - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ranibizumab 10 mg/ml - 10 mg/ml